Articles From: Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes to MetLife Statement on Preliminary SIFI Designation


Core Phase III clinical trial program complete; BIL showed consistent HbA1c superiority against comparators Lilly expects U.S. and European regulatory submissions by end of Q1 2015 INDIANAPOLIS , Sept.
Sign-up for Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes investment picks
HOUSTON, Sept.
Sign-up for LINN Energy Announces $1.0 Billion Senior Notes Offering investment picks
HOUSTON, Sept.
Sign-up for LINN Energy Announces Pricing of $1.1 Billion of Senior Notes investment picks
LAS VEGAS, Sept.
Sign-up for LiveDeal Inc. to Retain Byron Hsu as CEO and CTO of Subsidiary ModernEveryday investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0966414001&sourceType=1 http://www.ccnmatthews.com/logos/20080429-LUNLOGO.JPG TORONTO, ONTARIO --
Sign-up for Lundin Reports 2014 Mineral Reserve & Resource Estimate Update investment picks
HOUSTON and LONDON , Sept.
Sign-up for LyondellBasell to Address UBS Best of Americas 2014 Conference investment picks
2014/9/4
Data Integration across the Supply Chain: From Art, to Part, to Fulfillment LATROBE, Pa.
Sign-up for Made In The Cloud: Meet The Companies Leading The Manufacturing Sector's Digital Revolution investment picks
2014/9/4
YAHUD, Israel , Sept.
Sign-up for Magal Security Systems Reports Second Quarter 2014 Financial Results investment picks
Agreement Signed with Indiana Farm for the Sterilization of Manure and Use of MagneGas® TAMPA, Fla.
Sign-up for MagneGas Signs Agreement with Major Hog Farm for Demo and Sale of Sterilization System investment picks
Generates $11.0 Million Realized Gain and 25.1% Internal Rate of Return from Exit of Investment in American Sensor Technologies, Inc. HOUSTON , Sept.
Sign-up for Main Street Announces Exit of Portfolio Investment investment picks
Mallinckrodt (NYSE: MNK) today reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs.
Sign-up for Mallinckrodt Pharmaceutical’s MNK-155, an Extended-Release Hydrocodone/Acetaminophen Combination, Shows Efficacy in Phase 3 Acute Pain Trial investment picks
Group Presentation Set for 11:30 AM PT BRIDGEVIEW, Ill.
Sign-up for Manitex International, Inc. to Present at the RBC Global Industrials Conference on September 10, 2014 investment picks
NEW YORK, Sept.
Sign-up for MarketAxess Announces Monthly Volume Statistics for August 2014 investment picks
AKRON, Ohio , Sept.
Sign-up for Maryland Educators Reminded to Apply for Education Grants by September 19 investment picks
Mattress Firm Holding Corp.
Sign-up for Mattress Firm Announces Second Fiscal Quarter Financial Results investment picks
2014/9/4
NEW YORK , Sept.
Sign-up for MDC Partners to Present at the Goldman Sachs 23rd Annual Communacopia Conference investment picks
Mead Johnson Nutrition Company (NYSE: MJN) announced today that its board of directors has declared a regular quarterly common stock dividend of $0.375 per share for the quarter ending September 30, 2014.
Sign-up for Mead Johnson Board of Directors Declares Dividend investment picks
2014/9/4
MEDIA ADVISORY - TD Bank Group Executive to Present at the CIBC 13th Annual Eastern Institutional Investor Conference Canada NewsWire TORONTO , Sept.
Sign-up for MEDIA ADVISORY - TD Bank Group Executive to Present at the CIBC 13th Annual Eastern Institutional Investor Conference investment picks
Health Coaches 'Walk Across America' to Spread the Importance of a Healthy Lifestyle OWINGS MILLS, Md.
Sign-up for Medifast's Take Shape For Life Division Hosts 2nd Annual National "Discover Your Optimal Health" Day investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Sign-up for Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status.
Sign-up for Merck’s Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA investment picks
BOSTON, Sept.
Sign-up for Merger With Hillshire Moves Tyson Forward Faster investment picks
http://media.marketwire.com/attachments/201211/54409_Methodelogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1142033&ProfileId=051205&sourceType=1 CHICAGO, IL --
Sign-up for Methode Electronics, Inc. Reports Fiscal 2015 First-Quarter Sales Growth of 30 Percent and Income From Operations Growth of 87 Percent investment picks
MetLife, Inc. (NYSE:MET) Chairman, President and Chief Executive Officer Steven A.
Sign-up for MetLife Statement on Preliminary SIFI Designation investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes to MetLife Statement on Preliminary SIFI Designation
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices